|
|
|
MitoProd patented technology for RNA manufacturing and its novel circular interfering RNA
* MitoProd SA, 146 rue Léo Saignat, 33076 Bordeaux, France - ** CNRS (Centre National de la Recherche Scientifique), Bordeaux, France
Here is a description of MitoProd patented technology for RNA manufacturing, permitting a recurring production of RNA in industrial quantities. This technology enables the production of custom RNA at a gram scale, 99 % full length and 95% pure. MitoProd has also designed a new class of interfering RNA called ciRNA®, which have improved features such as RNAses resistance and an increased in vivo efficiency compared to siRNAs.
|
MicroRNA-23b negatively regulates urokinase and c-met and inhibits migration of human hepatocellular carcinoma cells.
University of Brescia
By bioinformatics we predicted that miR-23b could recognize two sites in the 3’ UTR of uPA (urokinase-type plasminogen activator) and four sites in the 3’ UTR of c-met (hepatocyte growth factor receptor). miR-23b transfections in SKHep1C3 caused uPA and c-met decreased and migration and proliferation inhibition of SKHep1C3; anti-miR-23b transfection in human fibroblasts upregulated uPA and c-met. uPA and c-met shared a common microRNA that negatively regulates their expression.
|
Profiling formalin-fixed, paraffin-embedded (FFPE) samples on three Agilent microarray platforms
Genentech
Thousands of formalin-fixed, paraffin-embedded (FFPE) samples from clinical archives are available for retrospective studies. Such samples could provide crucial information for drug target discovery and diagnostics of various diseases. Here we used FFPE samples and their matched fresh-frozen (FF) counterparts to examine their performance on three types of microarrays including whole genome expression, comparative genomic hybridization (CGH) and microRNA.
|
|
|
|
|
|
Compound Management Technologist, St Jude Children's Research Hospital, Memphis, TN
St. Jude Children's Research Hospital, located in Memphis, Tennessee, is a premier center for research and treatment of potentially fatal childhood diseases, including cancer and certain blood, genetic, and immunodeficiency disorders. The hospital's mission is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. St. Jude is dedicated to providing unsurpassed patient care and to advancing the health of children through biomedical research.
|
|
|
Postdoctoral Research Associate
Northeastern University
The Center for Drug Discovery at Northeastern University is dedicated to designing and discovering novel medications, developing technologies, and training scientists in the multidisciplinary field of drug discovery. We are recruiting a Postdoctoral Research Associate with expertise in protein-based mass spectrometry and /or proteomics.
|
|
|
Product Manager - Techne, Stone, Staffordshire
Bibby Scientific
Bibby Scientific Ltd is one of the world’s leading manufacturers of Laboratory bench-top scientific equipment. For more information about the company, please visit their website (www.bibby-scientific.com).
|
|
|
Assistant/Associate Professors
Chinese University of Hong Kong
The newly established School of Biomedical Sciences, Stem Cell and Regeneration theme is actively looking for stem cell biologist over the next 2 years.
|
|
|
Macromolecular X-ray Crystallgrapher
Xtal Biostructures
Ph.D. Protein Crystallographer: We seek an experienced crystallographer with post-doctoral experience to participate in a number of our diverse structural biology activities.
|
|
|
Marketing Communications Specialist Position in San Jose, CA
Thermo Fisher Scientific
This position, based in San Jose, CA within the SID Division, will manage promotion of Thermo Scientific mass spectrometry products and services.
|
|
|
|
RNAi2010: 5th International Oxford RNAi Conference, St Hilda’s College, Oxford
17 March 2010 - 18 March 2010
Welcome to RNAi2010: 5th International Oxford RNAi Conference, 17-18 March 2010, St Hilda’s College, Oxford, UK. Abstract submission deadline for both podium and poster abstracts is 18 December 2009. Pay using GoogleCheckout.
|
RNAi & miRNA World Congress, Boston, USA
05 May 2010 - 07 May 2010
Since the discovery of RNAi in 1998 progression in the field of RNA studies and therapies has been rapid. The 3rd RNAi World Congress meeting has been extended to include a focus on microRNAs as well as the latest developments in RNA-based Therapeutics and siRNA research and technologies.
|
Genomics Automation World Congress, Boston, USA
06 May 2010 - 07 May 2010
This conference will focus on the latest technology and techniques surrounding genomics research. Sample Preparation and Storage will be discussed alongside the latest technology in DNA Sequencing, (including Next Generation Sequencing), Data Analysis and Storage.
|
Epigenetics World Congress, Boston, MA, USA
06 May 2010 - 07 May 2010
After being introduced last year in Europe, this inaugural US conference will explore the latest on the rapidly expanding field of epigenetics. Topics will include Gene Silencing, Chromatin Remodelling and ncRNA with a focus on the Epigenetics of Disease and Development.
|
|
| |
|
|
|
|
|
|
Rescue of Pituitary Function in a Mouse Model of Isolate Growth Hormone Deficiency Type II by RNAi
James Patton, Professor, Vanderbilt University, speaking at RNAi World Congress 2009
|
|
|
TPI ASM8 and TPI 1100 – Development of Multi-Targeted Antisense Approaches for the Treatment of Lung Inflammatory Diseases
Nickolay Ferrari, Director of Pharmacology, Topigen, speaking at RNAi World Congress 2009
|
|
Impact of Target Secondary Structure on Function of Small RNAs
Ye Ding, Research Scientist, Wadsworth Center, Developmental Genetics and Bioinformatics, speaking at RNAi World Congress 2009
|
|
|
|
Epigenetics, Pluripotency, and Reprogramming 2009
Select Biosciences Ltd
Epigenetics technology and market landscape is analyzed in detail along with the therapeutics pipeline and opportunities therein. Cellular reprogramming and the iPSC phenomenon from both a technical as well as market-focused perspective are analyzed. A qualitative and quantitative analysis of the epigenetics and pluripotency market are presented.
|
MicroRNA Diagnostics, Therapeutics, and Cancer Personalized Medicine 2009.
Select Biosciences Ltd
Latest primary market data, market metrics (size, growth rates), technologies, and product offerings are presented and analyzed for cancer personalized medicine as well as the broader personalized medicine space. MicroRNA diagnostics and therapeutics marketplace is analyzed along with the competitive landscape.
|
|
|
|
Nucleofection® Enables Luciferase Reporter Assays in Primary Cells and Virtually Any Cell Line
Amaxa GMBH
The combination of Promega’s luciferase products and amaxa's Nucleofector® Technology enables researchers to obtain much more significant results with physiologically relevant cells. In this technical note, we give suggestions for Nucleofection® of luciferase constructs and an overview about the wide range of possible applications.
|
RNAi-mediated CD2 suppression in primary human T cells
Amaxa GMBH
The down-regulation of gene expression using small interfering RNA (siRNA) has become the method of choice for functional gene analysis in cells. Data presented in this application note show that CD2 expression can be specifically down-regulated in both resting and activated primary human T cells via the Nucleofection® of CD2 specific siRNA molecules.
|
|